A director of Parabilis Medicines purchased $474,000 worth of company stock in the open market just days after its initial public offering. Director Alan Sebulsky acquired 17,500 shares across multiple transactions on June 12 and June 15, 2026, at a weighted-average price of $27.06 per share, according to an SEC filing. The purchase increased his indirect holdings through Apothecary Capital LLC to 30,000 shares, while his direct holdings remained at zero. The buy price was approximately 8.2% above the June 15 market close of $25.85, and the transaction represents the largest single reported addition to his indirect position to date. Parabilis Medicines, a clinical-stage biotechnology company developing cell-penetrating miniproteins for oncology, went public on June 10 with an upsized IPO that priced shares at $20.
Parabilis Medicines, Inc. Common StockDirector bought $474k stock days after IPO, signaling insider confidence
Jazz Pharmaceuticals PLC